Telomir Pharmaceuticals Unveils Pre-Clinical Data On Age-Reversal Drug Telomir-1 At National Press Club Event in Washington, D.C.

4/16/24 8:39:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TELO alert in real time by email

Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging

Demonstrated a 40% increase in telomerase activity and lengthened telomeres in vitro in human cells

Provided pre-clinical endpoints to determine "anti-aging" and "age-reversal" effects in dogs

Outlined timeline for initiating human investigational new drug (IND) trials for osteoarthritis, along with animal IND (AIND) trials

Get the next $TELO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TELO

Date	Price Target	Rating	Analyst

More analyst ratings

$TELO
Press Releases

Fastest customizable press release news feed in the world

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader in age-reversal science, today announced groundbreaking preclinical results confirming the efficacy of Telomir-1, a compound designed to effectively turn back the biological clock and support longevity.Using advanced in vivo microfluidic technology, in collaboration with Nagi Biosciences SA, the study demonstrates significant age-reversal effects in aging model organisms treated with Telomir-1, effectively turning back the biological clock. These effects include an extended healthy lifespan, improved mobility, and a measurable reversal of age-related decli
11/21/24 7:00:00 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Interview to Air Sunday, September 29, 2024 at 5:30 PM EST on Fox Business NetworkMIAMI, FL / ACCESSWIRE / September 26, 2024 / Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company seeking to lead developments in longevity science through the treatment of age-related conditions, is proud to announce that the Telomir will be featured on Health Uncensored with Dr. Drew this Sunday, September 29, 2024 at 5:30 PM EST / 2:30 PM PT on Fox Business Network.In this episode, Telomir Pharmaceuticals' Special Advisor, Dr. Michael F. Roizen, MD, Emeritus Chief Wellness Officer at Cleveland Clinic, will join Dr. Drew Pinsky to discuss the science o
9/26/24 4:00:00 PM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
MIAMI, FL / ACCESSWIRE / September 4, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, is pleased to announce the appointment of Dr. Itzchak Angel as Chief Scientific Advisor.Dr. Angel, in collaboration with Telomir's senior management, will look to expedite the pre-clinical and clinical path of Telomir's lead product candidate, Telomir-1, a novel small molecule designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process.Telomir is presently optimizing drug production and forming strategic partnersh
9/4/24 7:30:00 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care

$TELO
Market Insights

Live Market Insights

Telomir Pharmaceuticals Added To Russell 3000 And Russell Microcap Indexes
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA's protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.
7/2/24 8:34:53 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
Telomir Pharmaceuticals Commences Two Milestones For Telomir-1
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine study on May 28th with initial dosing of Telomir-1 – All Animals Tolerated Dosing Well – Data will explore the potential for treatment of age-related conditions
5/30/24 8:36:57 AM ET
$TELO
Biotechnology: Pharmaceutical Preparations
Health Care
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Predictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 18.25% to $0.45. The company's market cap stands at $30.5 million. Telomir Pharmaceuticals (NASDAQ:TELO) stock increased by 12.92% to $7.34. The market value of their outstanding shares is at $217.3 million. NRX Pharmaceuticals (NASDAQ:NRXP) stock increased by 11.24% to $2.87. The market value of their outstanding shares is at $30.1 million. TransMedics Gr (NASDAQ:TMDX) shares moved upwards by 11.02% to $104.51. The company's market cap stands at $3.4 billion. As per the press re
4/30/24 4:31:25 PM ET
$AKTX
$BCLI
$CCM
$CVRX
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Nursing Services

Telomir Pharmaceuticals Unveils Pre-Clinical Data On Age-Reversal Drug Telomir-1 At National Press Club Event in Washington, D.C.

Chat with this insight

Recent Analyst Ratings for
$TELO

$TELO
SEC Filings

Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by Telomir Pharmaceuticals Inc.

$TELO
Press Releases

Fastest customizable press release news feed in the world

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

$TELO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Financial Officer Yanez Michelle

SEC Form 4 filed by Director Macpherson Edward Clouston

SEC Form 4 filed by Director Jerman Michael Allen

$TELO
Leadership Updates

Live Leadership Updates

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

$TELO
Market Insights

Live Market Insights

Telomir Pharmaceuticals Added To Russell 3000 And Russell Microcap Indexes

Telomir Pharmaceuticals Commences Two Milestones For Telomir-1

12 Health Care Stocks Moving In Tuesday's After-Market Session

Telomir Pharmaceuticals Unveils Pre-Clinical Data On Age-Reversal Drug Telomir-1 At National Press Club Event in Washington, D.C.

Chat with this insight

Recent Analyst Ratings for $TELO

$TELO SEC Filings

Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update

Telomir Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

SEC Form 10-Q filed by Telomir Pharmaceuticals Inc.

$TELO Press Releases

Fastest customizable press release news feed in the world

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

$TELO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Chief Financial Officer Yanez Michelle

SEC Form 4 filed by Director Macpherson Edward Clouston

SEC Form 4 filed by Director Jerman Michael Allen

$TELO Leadership Updates

Live Leadership Updates

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

$TELO Market Insights

Live Market Insights

Telomir Pharmaceuticals Added To Russell 3000 And Russell Microcap Indexes

Telomir Pharmaceuticals Commences Two Milestones For Telomir-1

12 Health Care Stocks Moving In Tuesday's After-Market Session

Recent Analyst Ratings for
$TELO

$TELO
SEC Filings

$TELO
Press Releases

$TELO
Insider Trading

$TELO
Leadership Updates

$TELO
Market Insights